Phase 2A Multi-Centre, Double Blind, Placebo Controlled 3-Way Cross-Over Study To Investigate The Effect Of Single Doses Of PF-00446687 On Sexual Arousal And Sexual Desire In Women Suffering From Female Sexual Dysfunction (FSD).

Trial Profile

Phase 2A Multi-Centre, Double Blind, Placebo Controlled 3-Way Cross-Over Study To Investigate The Effect Of Single Doses Of PF-00446687 On Sexual Arousal And Sexual Desire In Women Suffering From Female Sexual Dysfunction (FSD).

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2013

At a glance

  • Drugs PF 446687 (Primary)
  • Indications Female sexual dysfunction
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 24 Mar 2012 Planned number of patients changed from 23 to 24 as reported by European Clinical Trials Database record.
    • 06 Jun 2008 Status changed from recruiting to completed according to ClinicalTrials.gov.
    • 23 Oct 2007 New trial centres added.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top